According to Reuters, Lilly could offer the lowest dose of its popular weight loss drug Zepbound at $149 a month, and Novo’s ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

Novo Nordisk stock slid Wednesday after the Danish drugmaker’s third-quarter results missed estimates, and it trimmed its ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Novo Nordisk has cut its outlook for 2025 as lower expectations for glucagon-like peptide-1 receptor agonists (GLP-1RA) continue to hit the drugmaker. Net profit for Q3 came in at Dkr20bn ($3.1bn), ...

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as the companies are nearing to strike U.S. pricing deals for ...

Investing.com -- U.S. President Donald Trump is expected to announce a deal with officials from Eli Lilly and Novo Nordisk that would cut the price of weight loss drugs to $150 a month in some cases, ...